Evidence map›Paper›PMID 41613239›Full record

ArticleRSC advances2026

Chromatography's evolution, unlocking affinity's new solution: potential-controlled affinity membrane chromatography.

Tobias Steegmüller, Maeliss Nzokam, Christian Sieg, David Golonka, Nina Fridley, Sebastian P Schwaminger, Sonja Berensmeier

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tobias SteegmüllerSchool of Engineering and Design, Technical University of Munich Boltzmannstraße 15 85748 Garching bei München Germany s.berensmeier@tum.de.ORCID https://orcid.org/0000-0002-5383-3538
Maeliss NzokamSchool of Engineering and Design, Technical University of Munich Boltzmannstraße 15 85748 Garching bei München Germany s.berensmeier@tum.de.
Christian SiegWaters | Wyatt Technology Hochstraße 12a 56307 Dernbach Germany.
David GolonkaWaters | Wyatt Technology Hochstraße 12a 56307 Dernbach Germany.ORCID https://orcid.org/0000-0003-4101-4591
Nina FridleySchool of Engineering and Design, Technical University of Munich Boltzmannstraße 15 85748 Garching bei München Germany s.berensmeier@tum.de.
Sebastian P SchwamingerNanoLab, Division of Medicinal Chemistry, Otto Loewi Research Center, Medical University of Graz Neue Stiftingtalstraße 6 8010 Graz Austria sebastian.schwaminger@medunigraz.at.
Sonja BerensmeierSchool of Engineering and Design, Technical University of Munich Boltzmannstraße 15 85748 Garching bei München Germany s.berensmeier@tum.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody purification is key to advancing immunotherapy, but high costs in traditional affinity chromatography remain a barrier. In response, we present a breakthrough technology for purifying antibodies from human blood plasma (HBP) and cell culture supernatant using a potential-controlled method. This innovative platform applies an electrical potential to efficiently elute up to 95% of bound antibodies from Protein A affinity membranes at optimal voltages of +2.5 to 3 V, all without the need for buffer exchange. Antibody quality, analyzed

Identifiers

PMID41613239
PMCPMC12850475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.